title: Oxidant/antioxidant status in patients with Raynaud's disease.
abstract: OBJECTIVE
  Despite several studies concerning the oxidative stress in Raynaud's phenomenon secondary to systemic sclerosis (secondary Raynaud, SR), little is known regarding the relationship between Raynaud's disease (primary Raynaud, PR) and oxidative stress at present. The aim of the present research was to study the parameters of oxidative stress in PR patients and to compare them to those of SR patients.
  
  
  METHODS
  Serum hydroperoxide (Hydrop) level, serum total antioxidant capacity (TAC) and serum total thiol (-SHp) barrier were measured in 19 patients with SR, 15 patients with PR and 14 healthy control subjects (CS). The statistical contrasts were performed via one-way ANOVA.
  
  
  RESULTS
  The serum Hydrop concentrations were significantly higher in SR (p = 0.0043) and PR (p = 0.0038) groups in comparison with CS. A significant decrease in serum TAC level in SR (p = 0.00005) and PR (p = 0.00128) patients in respect to the CS was revealed. No significant change in the -SHp barrier in SR and PR patients in respect to CS has been demonstrated. However, there were no significant differences in serum Hydrop and TAC levels between the groups of patients.
  
  
  CONCLUSIONS
  The study of serum oxidative stress parameters, in terms of Hydro and TAC levels may be used as a routine and rapid test to verify the oxidative stress status in SR and PR patients and to undertake a strategy of treatments by a supplementation of antioxidant molecules.
authors.affiliation: Department of Internal Medicine and Dermatology Unit, Perugia University School of Medicine, S. Maria General Hospital, Terni, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Biondi
authors.forename: S
authors.initials: S
authors.lastname: Coaccioli
authors.forename: S
authors.initials: S
authors.lastname: Lattanzi
authors.forename: A
authors.initials: A
authors.lastname: Puxeddu
authors.forename: M
authors.initials: M
authors.lastname: Papini
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000032:analysis*; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D006861:Hydrogen Peroxide / Q000097:blood* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009097:Multienzyme Complexes / Q000378:metabolism; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism; D016877:Oxidants / Q000097:blood*; D018384:Oxidative Stress; D011928:Raynaud Disease / Q000097:blood* / Q000209:etiology; D012594:Scleroderma, Localized / Q000097:blood / Q000150:complications; D012595:Scleroderma, Systemic / Q000097:blood / Q000150:complications; D013438:Sulfhydryl Compounds / Q000097:blood*; D013481:Superoxides / Q000378:metabolism
chemical_list: D000975:Antioxidants; D009097:Multienzyme Complexes; D016877:Oxidants; D013438:Sulfhydryl Compounds; D013481:Superoxides; D006861:Hydrogen Peroxide; C023107:NADH oxidase; D009247:NADH, NADPH Oxidoreductases